Vaccine Design against Chagas Disease Focused on the Use of Nucleic Acids

Chagas disease is caused by the protozoan and is endemic to Central and South America. However, it has spread around the world and affects several million people. Treatment with currently available drugs cause several side effects and require long treatment times to eliminate the parasite, however,...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2022-04, Vol.10 (4), p.587
Main Authors: Maldonado, Edio, Morales-Pison, Sebastian, Urbina, Fabiola, Solari, Aldo
Format: Article
Language:English
Subjects:
Adjuvants
Antigens
Cardiomyopathy
Chagas disease
Chronic effects
Chronic illnesses
Congenital diseases
Design
DNA vaccine
Drugs
Etiology
Glycoproteins
immune responses
Infectious diseases
Nucleic acids
pandemic
Parasites
Peptides
Proteins
Protozoa
Review
RNA vaccine
Severe acute respiratory syndrome coronavirus 2
Side effects
Surface antigens
Tropical diseases
Trypanosoma cruzi
vaccine delivery
Vaccines
Vector-borne diseases
Viral diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chagas disease is caused by the protozoan and is endemic to Central and South America. However, it has spread around the world and affects several million people. Treatment with currently available drugs cause several side effects and require long treatment times to eliminate the parasite, however, this does not improve the chronic effects of the disease such as cardiomyopathy. A therapeutic vaccine for Chagas disease may be able to prevent the disease and improve the chronic effects such as cardiomyopathy. This vaccine would be beneficial for both infected people and those which are at risk in endemic and non-endemic areas. In this article, we will review the surface antigens of , in order to choose those that are most antigenic and least variable, to design effective vaccines against the etiological agent of Chagas disease. Also, we discuss aspects of the design of nucleic acid-based vaccines, which have been developed and proven to be effective against the SARS-CoV-2 virus. The role of co-adjuvants and delivery carriers is also discussed. We present an example of a chimeric trivalent vaccine, based on experimental work, which can be used to design a vaccine against Chagas disease.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines10040587